Glaukos Corporation is an ophthalmic medical technology company dedicated to advancing the treatment of glaucoma, a leading cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS), aiming to transform traditional glaucoma management practices. Their flagship product, the iStent®, launched in the United States in 2012, is a micro-bypass stent designed to be used alongside cataract surgery to help reduce intraocular pressure in patients with mild to moderate open-angle glaucoma. Glaukos continues to expand its product offerings with innovative therapies, including the iStent SA, a trabecular micro-bypass system that features a two-stent design for standalone procedures. Founded in 1998 and based in San Clemente, California, Glaukos is committed to developing a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and their progression.
Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.
DOSE Medical Corp.
Acquisition in 2019
DOSE Medical Corp. is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.